Dimensional Fund Advisors LP lifted its stake in IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) by 19.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,559,213 shares of the company’s stock after acquiring an additional 252,924 shares during the period. Dimensional Fund Advisors LP’s holdings in IVERIC bio were worth $27,969,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in ISEE. JPMorgan Chase & Co. grew its stake in IVERIC bio by 563.0% during the 1st quarter. JPMorgan Chase & Co. now owns 541,865 shares of the company’s stock worth $9,120,000 after buying an additional 460,137 shares during the last quarter. Bank of New York Mellon Corp grew its stake in IVERIC bio by 8.1% during the 1st quarter. Bank of New York Mellon Corp now owns 487,001 shares of the company’s stock worth $8,196,000 after buying an additional 36,387 shares during the last quarter. HighTower Advisors LLC purchased a new position in IVERIC bio during the 1st quarter worth $214,000. AlphaCrest Capital Management LLC purchased a new position in IVERIC bio during the 1st quarter worth $449,000. Finally, MetLife Investment Management LLC grew its stake in IVERIC bio by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 62,622 shares of the company’s stock worth $1,054,000 after buying an additional 22,329 shares during the last quarter.
Analyst Upgrades and Downgrades
ISEE has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of IVERIC bio in a research note on Thursday. B. Riley boosted their price target on IVERIC bio from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, February 21st. Finally, Jefferies Financial Group downgraded IVERIC bio from a “buy” rating to a “hold” rating and dropped their price target for the company from $30.00 to $20.00 in a research note on Thursday, November 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, IVERIC bio has an average rating of “Moderate Buy” and a consensus price target of $27.30.
Insider Transactions at IVERIC bio
IVERIC bio Stock Down 1.9 %
Shares of ISEE opened at $23.21 on Friday. IVERIC bio, Inc. has a 52 week low of $8.85 and a 52 week high of $26.35. The company has a quick ratio of 13.40, a current ratio of 18.63 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of -15.27 and a beta of 1.09. The stock’s 50-day moving average price is $21.08 and its 200-day moving average price is $19.66.
IVERIC bio (NASDAQ:ISEE – Get Rating) last issued its earnings results on Wednesday, March 1st. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.10). During the same period in the previous year, the firm posted ($0.29) earnings per share. On average, sell-side analysts predict that IVERIC bio, Inc. will post -1.58 EPS for the current year.
IVERIC bio Company Profile
IVERIC bio, Inc operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.
- Get a free copy of the StockNews.com research report on IVERIC bio (ISEE)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating).
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.